Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LavipharmATH:LAVI +0.26%80 EV-to-EBITDA is 20.17 as of Aug. 18, 2026, which is 120% above its 10-year median of 9.16. GuruFocus rates ATH:LAVI with a GF Score™ of 80/100 and a GF Value™ of €1.21 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 734 Drug Manufacturers companies, Lavipharm ranks worse than 66.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lavipharm's enterprise value is €293.66 Mil.
Lavipharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €14.56 Mil. Therefore, Lavipharm's EV-to-EBITDA for today is 20.17.
The historical rank and industry rank for Lavipharm's EV-to-EBITDA or its related term are showing as below:
ATH:LAVI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.7 Med: 9.16 Max: 21.95
Current: 20.17
During the past 9 years, the highest EV-to-EBITDA of Lavipharm was 21.95. The lowest was 2.70. And the median was 9.16.
ATH:LAVI's EV-to-EBITDA is ranked worse than 66.89% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.435
vs ATH:LAVI: 20.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lavipharm's share price for today is €1.564.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lavipharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.036.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Lavipharm's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATH:LAVI vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lavipharm's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lavipharm EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lavipharm's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lavipharm's EV-to-EBITDA falls into.
Lavipharm's current Enterprise Value is €293.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lavipharm's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €14.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lavipharm (ATH:LAVI) has a EV-to-EBITDA of 20.17 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lavipharm. This is 120% above median its historical median of 9.16. Over the past decade, Lavipharm's EV-to-EBITDA has ranged from 2.70 to 21.95. According to the industry distribution chart, Lavipharm ranks #491 out of 734 companies in the Drug Manufacturers industry, placing it in the top 66.9%.
Is Lavipharm's EV-to-EBITDA too high?
Lavipharm's current EV-to-EBITDA of 20.17 is 120% above median its 10-year median of 9.16. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 21.95. The Drug Manufacturers industry median EV-to-EBITDA is 13.44. Lavipharm's value of 20.17 is 50.1% above this industry median. Based on the distribution chart, Lavipharm ranks #491 out of 734 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lavipharm has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lavipharm ranks #491 out of 734 companies for EV-to-EBITDA. This places Lavipharm in the lower half of its industry. The industry median EV-to-EBITDA is 13.44. Lavipharm's value of 20.17 is 50.1% above this benchmark. Historically, Lavipharm's own EV-to-EBITDA has ranged from 2.70 to 21.95 over the past decade. While the company's 10-year median is 9.16 vs. the industry median of 13.44, Lavipharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.44, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lavipharm's current EV-to-EBITDA of 20.17 is 50.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lavipharm. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lavipharm's current EV-to-EBITDA is 20.17, which is 120% above median its own 10-year median of 9.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (ATH:LAVI) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.21, compared to a current price of €1.56 — trading 29.3% above its estimated fair value. The current EV-to-EBITDA is 20.17, which is 120% above median its 10-year median of 9.16 and 50.1% above the Drug Manufacturers industry median of 13.44. Lavipharm's overall GF Score™ is 80/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lavipharm (ATH:LAVI), the current EV-to-EBITDA is 20.17 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lavipharm (ATH:LAVI) Overvalued in 2026?
Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued.
The current stock price of €1.56 is trading 29.3% above its estimated GF Value™ of €1.21.
GuruFocus considers Lavipharm to be Modestly Overvalued.
Key valuation signals for ATH:LAVI:
EV-to-EBITDA: 20.17 (120% above median its 10-year median of 9.16)
GF Value™: €1.21 vs. price of €1.56 (29.3% above fair value)
Industry Position: 50.1% above the Drug Manufacturers median (#491 of 734)
No single metric tells the full story. See the ATH:LAVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
80GF Score
Get the complete analysis for ATH:LAVI
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATH:LAVI has been successfully added to your 
